Juan Jesús
Cruz Hernández
Profesor Emérito
Hospital General Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (16)
2021
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 764-772
2019
-
Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts
Journal of Pain Research, Vol. 12, pp. 2349-2358
2018
-
Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612
-
Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study
Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618
-
The quality oncology practice initiative program: Experience in Spain
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii570-viii571
2016
-
A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia
British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198
-
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study
Oral Oncology, Vol. 62, pp. 54-59
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2014
-
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
Annals of Oncology, Vol. 25, Núm. 1, pp. 216-225
-
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920
2010
-
Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50
-
SEOM clinical guidelines for the treatment of head and neck cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 742-748
2009
-
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients
Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736
2005
-
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5- fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study
European Journal of Cancer, Vol. 41, Núm. 9, pp. 1254-1260
2002
-
Estudio de la astenia tumoral: Constituci-acon del grupo ASTHENOS
Revista Clinica Espanola, Vol. 202, Núm. 10, pp. 525-528